OBJECTIVE: To highlight New Mexico's multifaceted approach to widespread pharmacy naloxone distribution and to share the interventions as a tool for improving pharmacy-based naloxone practices in other states. SETTING: New Mexico had the second highest drug overdose death rate in 2014 of which 53% were related to prescription opioids. Opioid overdose death is preventable through the use of naloxone, a safe and effective medication that reverses the effects of prescription opioids and heroin. Pharmacists can play an important role in providing naloxone to individuals who use prescription opioids. PRACTICE DESCRIPTION: Not applicable. PRACTICE INNOVATIONS: Not applicable. INTERVENTIONS: A multifaceted approach was utilized in New Mexico from the top down with legislative passage of provisions for a statewide standing order and New Mexico Department of Health support for pharmacy-based naloxone delivery. A bottom up approach was also initiated with the development and implementation of a training program for pharmacists and pharmacy technicians. EVALUATION: Naloxone Medicaid claims were used to illustrate statewide distribution and utilization of the pharmacist statewide standing order for naloxone. Percent of pharmacies dispensing naloxone in each county were calculated. Trained pharmacy staff completed a program evaluation form. Questions about quality of instruction and ability of trainer to meet stated objectives were rated on a Likert scale. RESULTS: There were 808 naloxone Medicaid claims from 100 outpatient pharmacies during the first half of 2016, a 9-fold increase over 2014. The "A Dose of Rxeality" training program evaluation indicated that participants felt the training was free from bias and met all stated objectives (4 out of 4 on Likert scale). CONCLUSIONS: A multi-pronged approach coupling state and community collaboration was successful in overcoming barriers and challenges associated with pharmacy naloxone distribution and ensured its success as an effective avenue for naloxone acquisition in urban and rural communities.
OBJECTIVE: To highlight New Mexico's multifaceted approach to widespread pharmacy naloxone distribution and to share the interventions as a tool for improving pharmacy-based naloxone practices in other states. SETTING: New Mexico had the second highest drug overdose death rate in 2014 of which 53% were related to prescription opioids. Opioid overdose death is preventable through the use of naloxone, a safe and effective medication that reverses the effects of prescription opioids and heroin. Pharmacists can play an important role in providing naloxone to individuals who use prescription opioids. PRACTICE DESCRIPTION: Not applicable. PRACTICE INNOVATIONS: Not applicable. INTERVENTIONS: A multifaceted approach was utilized in New Mexico from the top down with legislative passage of provisions for a statewide standing order and New Mexico Department of Health support for pharmacy-based naloxone delivery. A bottom up approach was also initiated with the development and implementation of a training program for pharmacists and pharmacy technicians. EVALUATION: Naloxone Medicaid claims were used to illustrate statewide distribution and utilization of the pharmacist statewide standing order for naloxone. Percent of pharmacies dispensing naloxone in each county were calculated. Trained pharmacy staff completed a program evaluation form. Questions about quality of instruction and ability of trainer to meet stated objectives were rated on a Likert scale. RESULTS: There were 808 naloxone Medicaid claims from 100 outpatient pharmacies during the first half of 2016, a 9-fold increase over 2014. The "A Dose of Rxeality" training program evaluation indicated that participants felt the training was free from bias and met all stated objectives (4 out of 4 on Likert scale). CONCLUSIONS: A multi-pronged approach coupling state and community collaboration was successful in overcoming barriers and challenges associated with pharmacy naloxone distribution and ensured its success as an effective avenue for naloxone acquisition in urban and rural communities.
Authors: Macarena C Garcia; Mark Faul; Nicole F Dowling; Cheryll C Thomas; Michael F Iademarco Journal: Public Health Rep Date: 2020-01-22 Impact factor: 2.792
Authors: Andrea Jakubowski; Alexander Pappas; Lee Isaacsohn; Felipe Castillo; Mariya Masyukova; Richard Silvera; Louisa Holaday; Evan Rausch; Sameen Farooq; Keith T Veltri; Chinazo O Cunningham; Marcus A Bachhuber Journal: Subst Abus Date: 2018-11-26 Impact factor: 3.716
Authors: Carlos Blanco; Mir M Ali; Aaron Beswick; Karen Drexler; Cheri Hoffman; Christopher M Jones; Tisha R A Wiley; Allan Coukell Journal: NAM Perspect Date: 2020-10-26
Authors: Robin A Pollini; Susannah Slocum; Jenny E Ozga; Rebecca Joyce; Ziming Xuan; Traci C Green; Alexander Y Walley Journal: J Am Pharm Assoc (2003) Date: 2022-03-19
Authors: Karen Suchanek Hudmon; Robin L Corelli; Carl de Moor; Alan J Zillich; Christine Fenlon; Lyndsay Miles; Alexander V Prokhorov; Susan M Zbikowski Journal: J Am Pharm Assoc (2003) Date: 2018-05-18
Authors: Travis Olives; Laurie A Willhite; Samantha C Lee; Danika K Evans; Ashley Jensen; Hsiao-Ting Regelman; Eric S McGillis Journal: West J Emerg Med Date: 2020-08-24